A Comparison Of Outcomes In Patients In New York Heart Association (NYHA) Class II Heart Failure When Treated With Eplerenone Or Placebo In Addition To Standard Heart Failure Medicines (EMPHASIS-HF)

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Pfizer
ClinicalTrials.gov Identifier:
NCT00232180
First received: September 30, 2005
Last updated: March 28, 2013
Last verified: March 2013
  Purpose

In an earlier study, eplerenone was shown to improve survival in patients who had heart failure immediately following a heart attack. However, it is not known how patients with established mild-to-moderate heart failure (NYHA Class II), who have the additional risk of sudden death, will respond if treated with eplerenone. In this trial, eplerenone plus standard heart failure medicines is being compared to placebo plus standard heart failure medicines in terms of an additional ability to prolong life and prevent re-hospitalizations for worsening heart failure in these patients.

The Data Safety Monitoring Committee (DSMC) observed during its conduct of the protocol-specified second interim analysis on the 6th of May, 2010 that the efficacy of eplerenone had met the pre-specified stopping rules in the protocol. As a result of the discussion between the DSMC and the Executive Steering Committee (ESC), the ESC recommended that EMPHASIS-HF should be terminated, Based on the convincing efficacy and the consideration that it would be unethical not to offer this treatment to patients, the ESC recommended that all the patients in the trial should be transferred to open-label eplerenone. The Open Label Extension eplerenone arm will last for 12 months. Eplerenone is not currently approved for the indication studied in this patient population.

On May 26, 2010, further enrollment into EMPHASIS-HF was stopped. The amendment is considered to be the most appropriate way to ensure that all the subjects who participated in the double-blind phase of the EMPHASIS-HF trial can be offered treatment with eplerenone


Condition Intervention Phase
Heart Failure
Drug: Eplerenone
Phase 3

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Endpoint Classification: Safety Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: The Effect Of Eplerenone Versus Placebo On Cardiovascular Mortality And Heart Failure Hospitalization In Subjects With NYHA Class II Chronic Systolic Heart Failure

Resource links provided by NLM:


Further study details as provided by Pfizer:

Primary Outcome Measures:
  • Number of Participants With First Occurrence of Cardiovascular (CV) Mortality or Hospitalization Due to Heart Failure (HF) (Adjudicated): Up to Cut-off Date [ Time Frame: Baseline (30 March 2006) up to 50 months (cut-off date: 25 May 2010) ] [ Designated as safety issue: Yes ]
    CV mortality is defined as death due to heart failure, myocardial infarction, cardiac arrhythmia, stroke or cerebral vascular accident (CVA), other CV cause (such as aneurysm or pulmonary embolism). Hospitalization due to HF is defined as an overnight stay, or longer, in a hospital environment (emergency room, observation unit or in-patient care, or similar facility including admission to a day care facility) due to HF as the primary reason for hospitalization as determined by the endpoint committee adjudicator.

  • Number of Participants With First Occurrence of Cardiovascular (CV) Mortality or Hospitalization Due to Heart Failure (HF) (Adjudicated) [ Time Frame: Baseline (30 March 2006) up to 59.5 months (complete DB phase: 18 March 2011) ] [ Designated as safety issue: Yes ]
    CV mortality is defined as death due to heart failure, myocardial infarction, cardiac arrhythmia, stroke or cerebral vascular accident (CVA), other CV cause (such as aneurysm or pulmonary embolism). Hospitalization due to HF is defined as an overnight stay, or longer, in a hospital environment (emergency room, observation unit or in-patient care, or similar facility including admission to a day care facility) due to HF as the primary reason for hospitalization as determined by the endpoint committee adjudicator.


Secondary Outcome Measures:
  • Number of Participants With First Occurrence of All-Cause Mortality or Heart Failure (HF) Hospitalization (Adjudicated) [ Time Frame: Baseline (30 March 2006) up to 50 months (cut-off date: 25 May 2010), 59.5 months (complete DB phase: 18 March 2011) ] [ Designated as safety issue: Yes ]
    Death due to any cause or first of occurrence HF hospitalization. HF hospitalization is defined as an overnight stay, or longer, in a hospital environment (emergency room, observation unit or in-patient care, or similar facility including admission to a day care facility) due to HF as the primary reason for hospitalization as determined by the endpoint committee adjudicator.

  • Number of Participants With First Occurrence of All-Cause Mortality (Adjudicated) [ Time Frame: Baseline (30 March 2006) up to 50 months (cut-off date: 25 May 2010), 59.5 months (complete DB phase: 18 March 2011) ] [ Designated as safety issue: Yes ]
    Death due to any cause.

  • Number of Participants With First Occurrence of Cardiovascular (CV) Mortality (Adjudicated) [ Time Frame: Baseline (30 March 2006) up to 50 months (cut-off date: 25 May 2010), 59.5 months (complete DB phase: 18 March 2011) ] [ Designated as safety issue: Yes ]
    CV mortality is defined as death due to heart failure, myocardial infarction, cardiac arrhythmia, stroke or cerebral vascular accident (CVA), other CV cause (such as aneurysm or pulmonary embolism).

  • Number of Participants With First Occurrence of All-Cause Hospitalization (Adjudicated) [ Time Frame: Baseline (30 March 2006) up to 50 months (cut-off date: 25 May 2010), 59.5 months (complete DB phase: 18 March 2011) ] [ Designated as safety issue: Yes ]
    Hospitalization due to any cause is defined as an overnight stay, or longer, in a hospital environment (emergency room, observation unit or in-patient care, or similar facility including admission to a day care facility).

  • Number of Participants With First Occurrence of Heart Failure (HF) Hospitalization (Adjudicated) [ Time Frame: Baseline (30 March 2006) up to 50 months (cut-off date: 25 May 2010), 59.5 months (complete DB phase: 18 March 2011) ] [ Designated as safety issue: Yes ]
    First occurrence of HF hospitalization. Hospitalization due to HF is defined as an overnight stay, or longer, in a hospital environment (emergency room, observation unit or in-patient care, or similar facility including admission to a day care facility) due to HF as the primary reason for hospitalization as determined by the endpoint committee adjudicator.

  • Number of Participants With First Occurrence of All-Cause Mortality or All-Cause Hospitalization (Adjudicated) [ Time Frame: Baseline (30 March 2006) up to 50 months (cut-off date: 25 May 2010), 59.5 months (complete DB phase: 18 March 2011) ] [ Designated as safety issue: Yes ]
    Death due to any cause or hospitalization due to any cause. Hospitalization due to any cause is defined as an overnight stay, or longer, in a hospital environment (emergency room, observation unit or in-patient care, or similar facility including admission to a day care facility).

  • Number of Participants With First Occurrence Of Heart Failure (HF) Mortality or Heart Failure (HF) Hospitalization (Adjudicated) [ Time Frame: Baseline (30 March 2006) up to 50 months (cut-off date: 25 May 2010), 59.5 months (complete DB phase: 18 March 2011) ] [ Designated as safety issue: Yes ]
    Death due to HF or first occurrence of HF hospitalization. Hospitalization due to HF is defined as an overnight stay, or longer, in a hospital environment (emergency room, observation unit or in-patient care, or similar facility including admission to a day care facility) due to HF as the primary reason for hospitalization as determined by the endpoint committee adjudicator.

  • Number of Participants With First Occurrence of Cardiovascular (CV) Hospitalization (Adjudicated) [ Time Frame: Baseline (30 March 2006) up to 50 months (cut-off date: 25 May 2010), 59.5 months (complete DB phase: 18 March 2011) ] [ Designated as safety issue: Yes ]
    First occurrence of CV hospitalization. CV hospitalization is defined as hospitalization due to HF (first or subsequent), acute myocardial infarction, angina pectoris (unstable), cardiac arrhythmia (atrial fibrillation [AF], atrial flutter, supraventricular arrhythmias, or ventricular arrhythmias), stroke/CVA, other CV reasons (such as hypotension or peripheral vascular disease), implantation of a cardioverter defibrillator (ICD), or cardiac resynchronization therapy (CRT) with CV event as the primary reason for hospitalization as determined by endpoint committee adjudicator.

  • Number of Participants With First Occurrence of Fatal or Non-fatal Myocardial Infarction (Adjudicated) [ Time Frame: Baseline (30 March 2006) up to 50 months (cut-off date: 25 May 2010), 59.5 months (complete DB phase: 18 March 2011) ] [ Designated as safety issue: Yes ]
  • Number of Participants With First Occurrence of Fatal or Non-fatal Stroke (Adjudicated) [ Time Frame: Baseline (30 March 2006) up to 50 months (cut-off date: 25 May 2010), 59.5 months (complete DB phase: 18 March 2011) ] [ Designated as safety issue: Yes ]
  • Number of Participants With First Occurrence of Implantation of Cardiac Defibrillator (ICD) (Adjudicated) [ Time Frame: Baseline (30 March 2006) up to 50 months (cut-off date: 25 May 2010), 59.5 months (complete DB phase: 18 March 2011) ] [ Designated as safety issue: Yes ]
    First occurrence of implantation of cardiac defibrillator (ICD). ICD is an electronic device capable of monitoring the heart rhythm. When the heart is beating normally, the device remains inactive. If the heart develops a life-threatening tachycardia, the ICD delivers electrical shocks to the heart to terminate the abnormal rhythm and return the heart rhythm to normal.

  • Number of Participants With First Occurrence of Implantation of Resynchronization Device (Cardiac Resynchronization Therapy [CRT]) (Adjudicated) [ Time Frame: Baseline (30 March 2006) up to 50 months (cut-off date: 25 May 2010), 59.5 months (complete DB phase: 18 March 2011) ] [ Designated as safety issue: Yes ]
    First occurrence of implantation of resynchronization device. CRT is use of a specialized pacemaker to re-coordinate the action of the right and left ventricles in heart failure.

  • Number of Participants With First Occurrence of Hospitalization Due to Worsening Renal Function (Adjudicated) [ Time Frame: Baseline (30 March 2006) up to 50 months (cut-off date: 25 May 2010), 59.5 months (complete DB phase: 18 March 2011) ] [ Designated as safety issue: Yes ]
    First occurrence of hospitalization due to worsening renal function. Hospitalization due to worsening renal function is defined as an overnight stay, or longer, in a hospital environment (emergency room, observation unit or in-patient care, or similar facility including admission to a day care facility) due to worsening renal function as the primary reason for hospitalization as determined by endpoint committee adjudicator. Worsening renal function is defined as doubling of serum creatinine level from baseline level.

  • Number of Participants With First Occurrence of Hospitalization Due to Hyperkalemia (Adjudicated) [ Time Frame: Baseline (30 March 2006) up to 50 months (cut-off date: 25 May 2010), 59.5 months (complete DB phase: 18 March 2011) ] [ Designated as safety issue: Yes ]
    First occurrence of hospitalization due to hyperkalemia. Hospitalization due to hyperkalemia is defined as an overnight stay, or longer, in a hospital environment (emergency room, observation unit or in-patient care, or similar facility including admission to a day care facility) due to hyperkalemia as the primary reason for hospitalization as determined by endpoint committee adjudicator. Hyperkalemia is defined as serum potassium level greater than (>) 5.5 milliequivalents per liter (mEq/L).

  • Number of Participants With New Onset Atrial Fibrillation or Flutter [ Time Frame: Baseline (30 March 2006) up to 50 months (cut-off date: 25 May 2010), 59.5 months (complete DB phase: 18 March 2011) ] [ Designated as safety issue: Yes ]
    New onset of atrial fibrillation or flutter is defined as the diagnosis of atrial fibrillation or flutter in a participant after randomization, where atrial fibrillation was not present before randomization.

  • Number of Participants With New Onset Diabetes Mellitus (DM) [ Time Frame: Baseline (30 March 2006) up to 50 months (cut-off date: 25 May 2010), 59.5 months (complete DB phase: 18 March 2011) ] [ Designated as safety issue: Yes ]
    The definition of new onset diabetes mellitus is the diagnosis of diabetes mellitus in a participant after randomization, when DM was not present before randomization.


Enrollment: 2743
Study Start Date: March 2006
Study Completion Date: January 2012
Primary Completion Date: May 2010 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Active Comparator: Eplerenone arm
Eplerenone administered on top of background standard heart failure therapy
Drug: Eplerenone
Eplerenone administered on top of background standard heart failure therapy

  Eligibility

Ages Eligible for Study:   55 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • History (Hx) of chronic systolic heart failure of ischemic or non-ischemic etiology of at least 4 weeks duration; Currently, New York Heart Association (NYHA) functional Class II and on optimal dose, or maximally tolerated dose of standard heart failure medicines (advisable to include ACE-I/ARBs; beta-blockers) and diuretics if indicated for fluid overload. Should have participated in the double-blind phase of the EMPHASIS-HF trial

Exclusion Criteria:

  • Severe chronic systolic heart failure symptomatic at rest despite optimal medical therapy; estimated glomerular filtration rate (eGFR) <30 ml/min/1.73m2.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00232180

  Hide Study Locations
Locations
United States, Arizona
Pfizer Investigational Site
Phoenix, Arizona, United States, 85008
United States, California
Pfizer Investigational Site
Loma Linda, California, United States, 92354
Pfizer Investigational Site
Merced, California, United States, 95340
Pfizer Investigational Site
Stockton, California, United States, 95204
United States, Colorado
Pfizer Investigational Site
Colorado Springs, Colorado, United States, 80909
United States, Connecticut
Pfizer Investigational Site
Bridgeport, Connecticut, United States, 06606
Pfizer Investigational Site
Hartford, Connecticut, United States, 06102
United States, District of Columbia
Pfizer Investigational Site
Washington, District of Columbia, United States, 20037
United States, Florida
Pfizer Investigational Site
Daytona Beach, Florida, United States, 32117
Pfizer Investigational Site
Gainesville, Florida, United States, 32608
Pfizer Investigational Site
Jupiter, Florida, United States, 33458
Pfizer Investigational Site
Melbourne, Florida, United States, 32901
United States, Illinois
Pfizer Investigational Site
Rockford, Illinois, United States, 61107
United States, Indiana
Pfizer Investigational Site
Indianapolis, Indiana, United States, 46260
Pfizer Investigational Site
Indianapolis, Indiana, United States, 46237
United States, Kentucky
Pfizer Investigational Site
Louisville, Kentucky, United States, 40202
Pfizer Investigational Site
Louisville, Kentucky, United States, 40205-3374
Pfizer Investigational Site
Louisville, Kentucky, United States, 40216
United States, Louisiana
Pfizer Investigational Site
Baton Rouge, Louisiana, United States, 70808
United States, Maine
Pfizer Investigational Site
Bangor, Maine, United States, 04401
United States, Maryland
Pfizer Investigational Site
Annapolis, Maryland, United States, 21401
Pfizer Investigational Site
Columbia, Maryland, United States, 21044-2914
United States, Massachusetts
Pfizer Investigational Site
Boston, Massachusetts, United States, 02118
United States, Minnesota
Pfizer Investigational Site
Minneapolis, Minnesota, United States, 55417
Pfizer Investigational Site
MN, Minnesota, United States, 55101
United States, Mississippi
Pfizer Investigational Site
Tupeelo, Mississippi, United States, 38801
Pfizer Investigational Site
Tupelo, Mississippi, United States, 38801-4600
United States, Nebraska
Pfizer Investigational Site
Omaha, Nebraska, United States, 68131
Pfizer Investigational Site
Omaha, Nebraska, United States, 68122
Pfizer Investigational Site
Omaha, Nebraska, United States, 68114
United States, New Hampshire
Pfizer Investigational Site
Manchester, New Hampshire, United States, 03102
United States, New York
Pfizer Investigational Site
Albany, New York, United States, 12208
Pfizer Investigational Site
Rochester, New York, United States, 14642
Pfizer Investigational Site
Rochester, New York, United States, 14618
United States, Ohio
Pfizer Investigational Site
Cincinnati, Ohio, United States, 45219
Pfizer Investigational Site
Cincinnati, Ohio, United States, 45267
United States, Oklahoma
Pfizer Investigational Site
Oklahoma City, Oklahoma, United States, 73112
Pfizer Investigational Site
Oklahoma City, Oklahoma, United States, 73104
United States, Pennsylvania
Pfizer Investigational Site
Beaver, Pennsylvania, United States, 15009
Pfizer Investigational Site
Doylestown, Pennsylvania, United States, 18901
Pfizer Investigational Site
Leetsdale, Pennsylvania, United States, 15056
Pfizer Investigational Site
Pittsburgh, Pennsylvania, United States, 15213
Pfizer Investigational Site
Pittsburgh, Pennsylvania, United States, 15212
United States, Rhode Island
Pfizer Investigational Site
Cumberland, Rhode Island, United States, 02864
United States, Tennessee
Pfizer Investigational Site
Germantown, Tennessee, United States, 38138
Pfizer Investigational Site
Knoxville, Tennessee, United States, 37917
United States, Texas
Pfizer Investigational Site
Dallas, Texas, United States, 75231
Pfizer Investigational Site
Dallas, Texas, United States, 75231-7906
Pfizer Investigational Site
Plano, Texas, United States, 75024
United States, Washington
Pfizer Investigational Site
Spokane, Washington, United States, 99204
United States, Wisconsin
Pfizer Investigational Site
Madison, Wisconsin, United States, 53792
Argentina
Pfizer Investigational Site
Moron, Pcia. de Buenos Aires, Argentina, 1708
Pfizer Investigational Site
Buenos Aires, Argentina, 1428
Pfizer Investigational Site
Cordoba, Argentina, X5003DCE
Australia, New South Wales
Pfizer Investigational Site
Concord, New South Wales, Australia, 2139
Australia, Queensland
Pfizer Investigational Site
Brisbane, Queensland, Australia, 4029
Australia, Tasmania
Pfizer Investigational Site
Launceston, Tasmania, Australia, 7250
Belgium
Pfizer Investigational Site
Antwerpen, Belgium, B-2020
Pfizer Investigational Site
Bonheiden, Belgium, B-2820
Pfizer Investigational Site
Eupen, Belgium, B-4700
Pfizer Investigational Site
Genk, Belgium, 3600
Pfizer Investigational Site
Hasselt, Belgium, 3500
Pfizer Investigational Site
Huy, Belgium, B-4500
Pfizer Investigational Site
La Louvière, Belgium, 7100
Pfizer Investigational Site
Lanaken, Belgium, 3620
Pfizer Investigational Site
Leuven, Belgium, 3000
Pfizer Investigational Site
Overpelt, Belgium, B-3900
Pfizer Investigational Site
Yvoir, Belgium, 5530
Canada, Ontario
Pfizer Investigational Site
Hamilton, Ontario, Canada, L8N 3Z5
Pfizer Investigational Site
Hamilton, Ontario, Canada, L8L 2X2
Pfizer Investigational Site
London, Ontario, Canada, N6A 5A5
Canada, Quebec
Pfizer Investigational Site
Montreal, Quebec, Canada, H4J 1C5
Pfizer Investigational Site
Montreal, Quebec, Canada, H3G 1A4
Pfizer Investigational Site
Montreal, Quebec, Canada, H1T 1C8
Pfizer Investigational Site
Sherbrooke, Quebec, Canada, J1H 5N4
Pfizer Investigational Site
St-Charles Borromee, Quebec, Canada, J6E 6J2
Pfizer Investigational Site
St-georges (Beauce), Quebec, Canada, G5Y 4T8
Canada
Pfizer Investigational Site
Quebec, Canada, G1V 4G5
Czech Republic
Pfizer Investigational Site
Brno, Czech Republic, 656 91
Pfizer Investigational Site
Brno, Czech Republic, 625 00
Pfizer Investigational Site
Hradec Kralove, Czech Republic, 500 05
Pfizer Investigational Site
Ostrava, Czech Republic, 708 52
Pfizer Investigational Site
Plzen, Czech Republic, 30599
Pfizer Investigational Site
Plzen, Czech Republic, 323 00
Pfizer Investigational Site
Praha 1, Czech Republic, 110 00
Pfizer Investigational Site
Praha 1, Czech Republic, 118 33
Pfizer Investigational Site
Praha 10, Czech Republic, 100 34
Pfizer Investigational Site
Praha 2, Czech Republic, 128 08
Pfizer Investigational Site
Praha 6, Czech Republic, 169 02
Pfizer Investigational Site
Pribram, Czech Republic, 261 01
France
Pfizer Investigational Site
Toulouse, Cedex 4, France, 31403
Pfizer Investigational Site
Creteil, Cedex, France, 94010
Pfizer Investigational Site
Gap, Cedex, France, 05000
Pfizer Investigational Site
Angers Cedex 01, France, 49033
Pfizer Investigational Site
Brest, France, 29200
Pfizer Investigational Site
Cergy-Pontoise, France, 95303
Pfizer Investigational Site
Chateauroux, France, 36019
Pfizer Investigational Site
Gap CEDEX, France, 05007
Pfizer Investigational Site
Nantes Cedex 01, France, 44093
Pfizer Investigational Site
Nice CEDEX 1, France, 06002
Pfizer Investigational Site
Nîmes, France, 30000
Pfizer Investigational Site
Paris CEDEX 13, France, 75651
Pfizer Investigational Site
St-Amand-Montrond, France, 18206
Pfizer Investigational Site
Strasbourg, France, 67098
Pfizer Investigational Site
Strasbourg, France, 67091
Pfizer Investigational Site
Valenciennes, France, 59300
Germany
Pfizer Investigational Site
Bad Nauheim, Germany, 61231
Pfizer Investigational Site
Bad Rothenfelde, Germany, 49214
Pfizer Investigational Site
Berlin, Germany, 12621
Pfizer Investigational Site
Berlin, Germany, 13125
Pfizer Investigational Site
Berlin, Germany, 12683
Pfizer Investigational Site
Berlin, Germany, 10367
Pfizer Investigational Site
Dortmund, Germany, 44137
Pfizer Investigational Site
Duisburg, Germany, 47137
Pfizer Investigational Site
Essen, Germany, 45122
Pfizer Investigational Site
Frankfurt/Main, Germany, 60594
Pfizer Investigational Site
Goettingen, Germany, 37075
Pfizer Investigational Site
Hagen, Germany, 58095
Pfizer Investigational Site
Halle, Germany, 06110
Pfizer Investigational Site
Hannover, Germany, 30625
Pfizer Investigational Site
Homburg/Saar, Germany, 66424
Pfizer Investigational Site
Koeln, Germany, 50924
Pfizer Investigational Site
Leipzig, Germany, 04289
Pfizer Investigational Site
Ludwigshafen, Germany, 67063
Pfizer Investigational Site
Luebeck, Germany, 23538
Greece
Pfizer Investigational Site
Athens, Attika, Greece, 16672
Pfizer Investigational Site
Haidari, Attiki, Greece, 12462
Pfizer Investigational Site
Athens, Greece, 14388
Pfizer Investigational Site
Athens, Greece, 11528
Pfizer Investigational Site
Athens, Greece, 10671
Pfizer Investigational Site
Athens, Greece, 11527
Pfizer Investigational Site
Thessaloniki, Greece, 54636
Pfizer Investigational Site
Thessaloniki, Greece, 54642
Pfizer Investigational Site
Thessaloniki, Greece, 57010
Hong Kong
Pfizer Investigational Site
Chai Wan, Hong Kong
Pfizer Investigational Site
Pokfulam, Hong Kong
Pfizer Investigational Site
Shatin NT, Hong Kong
Hungary
Pfizer Investigational Site
Budapest, Hungary, 1106
Pfizer Investigational Site
Budapest, Hungary, 1529
Pfizer Investigational Site
Budapest, Hungary, H-1134
Pfizer Investigational Site
Debrecen, Hungary, 4012
Pfizer Investigational Site
Mosonmagyarovar, Hungary, 9200
Pfizer Investigational Site
Siófok, Hungary, 8601
Pfizer Investigational Site
Szeged, Hungary, H-6720
India
Pfizer Investigational Site
Hyderabad, Andhra Pradesh, India, 500 034
Pfizer Investigational Site
Hyderabad, Andhra Pradesh, India, 500 001
Pfizer Investigational Site
Bangalore, Karnataka, India, 560 054
Pfizer Investigational Site
Bangalore, Karnataka, India, 560 034
Pfizer Investigational Site
Pune, Maharshtra, India, 411 004
Pfizer Investigational Site
Ludhiana, Punjab, India, 141 001
Pfizer Investigational Site
Chennai, Tamil Nadu, India, 400 037
Pfizer Investigational Site
Coimbatore, Tamil Nadu, India, 641 014
Pfizer Investigational Site
Lucknow, Uttar Pradesh, India, 226 014
Ireland
Pfizer Investigational Site
Cork, Ireland
Pfizer Investigational Site
Dublin, Ireland, Co.
Pfizer Investigational Site
Dublin, Ireland, 4
Pfizer Investigational Site
Galway, Ireland
Italy
Pfizer Investigational Site
Bergamo (BG), Italy, 24128
Pfizer Investigational Site
Catania, Italy, 95123
Pfizer Investigational Site
Catania, Italy, 95124
Pfizer Investigational Site
Firenze, Italy, 50134
Pfizer Investigational Site
Mestre - Zelardino (ve), Italy, 30164
Pfizer Investigational Site
Milano, Italy, 20138
Pfizer Investigational Site
Modena, Italy, 41100
Pfizer Investigational Site
Napoli, Italy, 80131
Pfizer Investigational Site
Padova, Italy, 35128
Pfizer Investigational Site
Palermo, Italy, 90100
Pfizer Investigational Site
Parma, Italy, 43100
Pfizer Investigational Site
Piacenza, Italy, 29100
Pfizer Investigational Site
Roma, Italy, 00163
Pfizer Investigational Site
Sassari, Italy, 07100
Pfizer Investigational Site
Trieste, Italy, 30147
Pfizer Investigational Site
Venezia, Italy, 30122
Korea, Republic of
Pfizer Investigational Site
Republic of Korea, Korea, Korea, Republic of, 120-752
Pfizer Investigational Site
Suwon, Korea, Republic of, 443-721
Pfizer Investigational Site
Taegu, Korea, Republic of, 700-721
Mexico
Pfizer Investigational Site
Aguascalientes, Aguacalientes, Mexico, 20230
Pfizer Investigational Site
Mexico, DF, Mexico, 02720
Pfizer Investigational Site
Guadalajara, Jalisco, Mexico, 44280
Pfizer Investigational Site
Zapopan, Jalisco, Mexico, 45200
Pfizer Investigational Site
Aguascalientes, Mexico, 20230
Pfizer Investigational Site
Chihuahua, Mexico, 31238
Pfizer Investigational Site
San Luis Potosi, Mexico, 78210
Netherlands
Pfizer Investigational Site
's-Hertogenbosch, Netherlands, 5211 NL
Pfizer Investigational Site
Alkmaar, Netherlands, 1815 JD
Pfizer Investigational Site
Apeldoorn, Netherlands, 7314 ET
Pfizer Investigational Site
Apeldoorn, Netherlands, 7334 DZ
Pfizer Investigational Site
Arnhem, Netherlands, 6815 AD
Pfizer Investigational Site
Breda, Netherlands, 4818 CK
Pfizer Investigational Site
Deventer, Netherlands, 7416 SE
Pfizer Investigational Site
Dordrecht, Netherlands, 3317 NM
Pfizer Investigational Site
Dordrecht, Netherlands, 3318 AT
Pfizer Investigational Site
Eindhoven, Netherlands, 5623 EJ
Pfizer Investigational Site
Groningen, Netherlands, 9713 GZ
Pfizer Investigational Site
Heerlen, Netherlands, 6419 PC
Pfizer Investigational Site
Veldhoven, Netherlands, 5504 DB
Pfizer Investigational Site
Velp, Netherlands, 6883 AZ
Pfizer Investigational Site
Zwolle, Netherlands, 8011 JW
Poland
Pfizer Investigational Site
Gdansk, Poland, 80-952
Pfizer Investigational Site
Krakow, Poland, 31-501
Pfizer Investigational Site
Lodz, Poland, 91-347
Pfizer Investigational Site
Piotrkow Trybunalski, Poland, 97-300
Pfizer Investigational Site
Poznan, Poland, 60-834
Pfizer Investigational Site
Stalowa Wola, Poland, 37-450
Pfizer Investigational Site
Szczecin, Poland, 71-455
Pfizer Investigational Site
Warszawa, Poland, 04-628
Pfizer Investigational Site
Warszawa, Poland, 02-097
Pfizer Investigational Site
Warszawa, Poland, 03-242
Portugal
Pfizer Investigational Site
Guilhufe - PNF, Penafiel, Portugal, 4560-162
Pfizer Investigational Site
Almada, Portugal, 2801-951
Pfizer Investigational Site
Amadora, Portugal, 2700-276
Pfizer Investigational Site
Coimbra, Portugal, 3000-075
Pfizer Investigational Site
Linda-a-Velha, Portugal, 2799-523
Pfizer Investigational Site
Lisboa, Portugal, 1769-001
Pfizer Investigational Site
Lisboa, Portugal, 1499-005
Pfizer Investigational Site
Oliveira de Azemeis, Portugal, 3720-275
Pfizer Investigational Site
Portalegre, Portugal, 7301-853
Pfizer Investigational Site
Porto, Portugal, 4200-319
Pfizer Investigational Site
Vila Franca de Xira, Portugal, 2600-178
Pfizer Investigational Site
Vila Real, Portugal, 5000
Russian Federation
Pfizer Investigational Site
Moscow, Russian Federation, 113093
Pfizer Investigational Site
Moscow, Russian Federation, 121552
Pfizer Investigational Site
Novosibirsk, Russian Federation, 630089
Pfizer Investigational Site
S-Petersburg, Russian Federation, 197022
Pfizer Investigational Site
S-Petersburg, Russian Federation, 192104
Pfizer Investigational Site
Saint-Petersburg, Russian Federation, 195257
Pfizer Investigational Site
Saint-Petersburg, Russian Federation, 196084
Pfizer Investigational Site
Voronezh, Russian Federation, 394053
Pfizer Investigational Site
Yaroslavl, Russian Federation, 150030
Singapore
Pfizer Investigational Site
Singapore, Singapore, 308433
Pfizer Investigational Site
Singapore, Singapore, 168752
Slovakia
Pfizer Investigational Site
Bratislava, Slovakia, 833 48
Pfizer Investigational Site
Bratislava, Slovakia, 813 69
Pfizer Investigational Site
Bratislava, Slovakia, 831 03
Pfizer Investigational Site
Bratislava, Slovakia, 811 05
Pfizer Investigational Site
Bratislava, Slovakia, 833 03
Pfizer Investigational Site
Levice, Slovakia, 934 01
Pfizer Investigational Site
Liptovsky Mikulas, Slovakia, 031 01
Pfizer Investigational Site
Nitra, Slovakia, 949 01
Pfizer Investigational Site
Trencin, Slovakia, 911 01
South Africa
Pfizer Investigational Site
Soweto, Johannesburg, South Africa, 2013
Pfizer Investigational Site
Bloemfontein, South Africa, 9300
Pfizer Investigational Site
Cape Town, South Africa, 7500
Pfizer Investigational Site
Cape Town, South Africa, 7405
Pfizer Investigational Site
Congella, South Africa, 4013
Pfizer Investigational Site
Johannesburg, South Africa, 2013
Pfizer Investigational Site
Kwazulu Natal, South Africa, 4001
Spain
Pfizer Investigational Site
Santiago de Compostela, La Coruña, Spain, 15706
Pfizer Investigational Site
Barakaldo, Vizcaya, Spain, 48903
Pfizer Investigational Site
Almeria, Spain, 04009
Pfizer Investigational Site
Barcelona, Spain, 08035
Pfizer Investigational Site
Cordoba, Spain, 14004
Pfizer Investigational Site
Malaga, Spain, 29010
Sweden
Pfizer Investigational Site
Angelholm, Sweden, 262 81
Pfizer Investigational Site
Bollnas, Sweden, 821 34
Pfizer Investigational Site
Falun, Sweden, 791 82
Pfizer Investigational Site
Goteborg, Sweden, 413 45
Pfizer Investigational Site
Goteborg, Sweden, 416 85
Pfizer Investigational Site
Göteborg, Sweden, 413 45
Pfizer Investigational Site
Göteborg, Sweden, SE-416 85
Pfizer Investigational Site
Halmstad, Sweden, 301 85
Pfizer Investigational Site
Hässleholm, Sweden, 281 31
Pfizer Investigational Site
Lindesberg, Sweden, 711 82
Pfizer Investigational Site
Linkoping, Sweden, 58185
Pfizer Investigational Site
Lulea, Sweden, 971 80
Pfizer Investigational Site
Molndal, Sweden, 431 80
Pfizer Investigational Site
Skelleftea, Sweden, S-931 86
Pfizer Investigational Site
Varberg, Sweden, 432 41
Pfizer Investigational Site
Vaxjo, Sweden, 351 85
Ukraine
Pfizer Investigational Site
Simferopol, Crimea, Ukraine, 95026
Pfizer Investigational Site
Dnipropetrovsk, Ukraine, 49005
Pfizer Investigational Site
Dnipropetrovsk, Ukraine, 49060
Pfizer Investigational Site
Dnipropetrovsk, Ukraine, 49023
Pfizer Investigational Site
Donetsk, Ukraine, 83003
Pfizer Investigational Site
Donetsk, Ukraine, 83114
Pfizer Investigational Site
Kharkiv, Ukraine, 61002
Pfizer Investigational Site
Kharkiv, Ukraine, 61000
Pfizer Investigational Site
Kiev, Ukraine, 03151
Pfizer Investigational Site
Kyiv, Ukraine, 04050
Pfizer Investigational Site
Kyiv, Ukraine, 02125
Pfizer Investigational Site
Lviv, Ukraine, 79013
Pfizer Investigational Site
Lviv, Ukraine, 79015
Pfizer Investigational Site
Odessa, Ukraine, 65039
Pfizer Investigational Site
Odessa, Ukraine, 65009
Pfizer Investigational Site
Uzhgorod, Ukraine, 88014
Pfizer Investigational Site
Zaporizhzhia, Ukraine, 69118
United Arab Emirates
Pfizer Investigational Site
Dubai, UAE, United Arab Emirates
Pfizer Investigational Site
Abu Dhabi, United Arab Emirates
United Kingdom
Pfizer Investigational Site
Knutsford, Cheshire, United Kingdom, WA16 0BT
Pfizer Investigational Site
Macclesfield, Cheshire, United Kingdom, SK10 3BL
Pfizer Investigational Site
Belfast, Northern Ireland, United Kingdom, BT12 6BA
Pfizer Investigational Site
Glasgow, Strathclyde, United Kingdom, G11 6NT
Pfizer Investigational Site
Belfast, United Kingdom, BT12 6BA
Pfizer Investigational Site
Coventry, United Kingdom, CVZ 2DX
Pfizer Investigational Site
Edinburgh, United Kingdom, EH4 2XU
Pfizer Investigational Site
Glasgow, United Kingdom, G12 8TA
Pfizer Investigational Site
Glasgow, United Kingdom, G11 6NT
Pfizer Investigational Site
Harrow, United Kingdom, HA1 3UJ
Pfizer Investigational Site
Larbert, United Kingdom, FK5 4WR
Pfizer Investigational Site
Macclesfield, United Kingdom, SK10 3BL
Pfizer Investigational Site
Manchester, United Kingdom, M23 9LT
Pfizer Investigational Site
Milton Keynes, United Kingdom, MK6 5LD
Pfizer Investigational Site
Sheffield, United Kingdom, S5 7AU
Pfizer Investigational Site
Southend-on-Sea, United Kingdom, SS0 0RY
Pfizer Investigational Site
Torquay, United Kingdom, TQ2 7AA
Venezuela
Pfizer Investigational Site
Caracas, Distrito Capital, Venezuela, 1061
Pfizer Investigational Site
Caracas, Estado Miranda, Venezuela, 1060
Pfizer Investigational Site
Caracas, Estado Miranda, Venezuela, 1061
Sponsors and Collaborators
Pfizer
Investigators
Study Director: Pfizer CT.gov Call Center Pfizer
  More Information

Additional Information:
No publications provided by Pfizer

Additional publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):

Responsible Party: Pfizer
ClinicalTrials.gov Identifier: NCT00232180     History of Changes
Other Study ID Numbers: A6141079
Study First Received: September 30, 2005
Results First Received: May 20, 2011
Last Updated: March 28, 2013
Health Authority: United States: Food and Drug Administration

Keywords provided by Pfizer:
Open-label
single arm mortality/morbidity trial eplerenone chronic systolic heart failure

Additional relevant MeSH terms:
Heart Failure
Heart Failure, Systolic
Heart Diseases
Cardiovascular Diseases
Eplerenone
Mineralocorticoid Receptor Antagonists
Hormone Antagonists
Hormones, Hormone Substitutes, and Hormone Antagonists
Physiological Effects of Drugs
Pharmacologic Actions
Diuretics, Potassium Sparing
Diuretics
Natriuretic Agents
Cardiovascular Agents
Therapeutic Uses

ClinicalTrials.gov processed this record on October 19, 2014